CJC-1295 is a redesigned copy of the hormone that tells your pituitary to release growth hormone. One version bonds to a protein in your blood, which stretches its life from minutes into days.
What matters first
Why people look it up
It is sold for the same wishlist as ipamorelin, and usually stacked with it: muscle, fat loss, recovery and sleep.
What the evidence shows
The human studies measured one thing, and it was growth hormone in the blood. None of them reported muscle, fat, strength or anything a person would notice. Most material sold under the name is the short-acting molecule, which was never in those studies.
Dose status
CJC-1295 is not FDA-approved, so no dosing label exists for it. The sections below explain what researchers tested and what remains unknown.
CJC-1295 at a glance: foreign approval or limited human data, dosing basis, regulatory status, safety coverage, and cited-source count. These details summarize the available sources; they are not treatment recommendations.
Evidence snapshot
Foreign approval or limited human data
The fastest way to see what kind of evidence this page is built on.
Regulation
Not FDA-approvedNo US prescribing label
Dose source
Human study2 reported dose rows
Safety evidence
5 listed safety findingsCommon and serious effects shown apart
CJC-1295 at a glance: foreign approval or limited human data, dosing basis, regulatory status, safety coverage, and cited-source count. These details summarize the available sources; they are not treatment recommendations.
Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewer·Reviewed 2026-08-12·open the primary sources
What is known about CJC-1295
CJC-1295 properly names a modified fragment of growth hormone-releasing hormone. The version studied in people carries a reactive chemical arm, the drug-affinity complex, which bonds the peptide to albumin in the blood. That stretches its life from minutes into days. Most material sold under the name has no such arm, so it is a different molecule: modified GRF 1-29, which clears fast. Phase 1 work showed the long-acting version raises growth hormone, but no trial showed what that achieves.
CJC-1295 research and regulatory details: evidence quality, approval status, doses, handling, and presentation.
Topic
Value
Strongest source
limited human data
FDA approval
Not FDA-approved
Studied dosing
30–60 mcg per kilogram of body weight — the two of four rising single-dose levels the authors singled out as safe and relatively easy for healthy adults aged 21 to 61 to handle, using the version carrying the drug-affinity complex; a single injection raised growth hormone 2- to 10-fold for six days or more and IGF-I 1.5- to 3-fold for nine to eleven days— from clinical trials
Studied dosing
60–90 mcg per kilogram of body weight, as a single injection, with growth hormone sampled overnight a week later in healthy men aged 20 to 40; the two doses did not differ from each other in effect— from clinical trials
What people report using
1–2 mg a week, split over one or two injections of the drug-affinity-complex version; the trials gave a single per-kilogram injection and then watched it for nine days, and nothing has tested a milligram quantity repeated weekly— no trial has tested this quantity
Typical vials
5 mg
Every row links back to a source listed below. These facts are for reference, not a personal recommendation.
The row headed “what people report using” is not evidence. No trial produced that quantity. It is printed because it is what circulates, and because it is better read here, beside what the studies actually did, than on a page that is selling the vial. It describes a practice. It is not a starting point.
What the evidence for CJC-1295 is
People have received this compound in a documented setting, or it has approval outside the United States. The available human evidence is still too limited to show a clear dose-and-result pattern for US use.
limited human data
What it establishes
It shows that people have received it and that some human information exists.
What it does not establish
It does not prove that the same dose is appropriate in the United States or that uncommon and long-term risks are known.
Check the country, study size and reason it was used. Do not treat limited human data as an FDA-approved schedule.
Where CJC-1295 is in clinical trials
1 registered study; the program has reached phase 2. Nothing is currently open or enrolling.
Phase 2Stopped early
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity
ConjuChem · Obesity, HIV Infections · 120 participants planned · started December 2005
A registered study means a sponsor filed a plan and started enrolling. It is not evidence the drug works, and most drugs tested in people never reach a pharmacy. Sponsors write and update these sources themselves; the National Library of Medicine publishes them without checking them.
One product name covers two substances here, and the difference is not cosmetic.
With the affinity complex the peptide lasts days; without it, minutes. So a protocol, a quantity or a risk written for one does not describe the other. Buyers routinely cannot tell which they hold.
The company that created the long-acting form dropped it, leaving no sponsor, no investigational filing and no pharmacopeial standard for either version.
Each page says which kind of comparison it is: one trial that tested both, or two separate trials read side by side — which is much weaker, however close the numbers look.
Two different molecules are sold under this one name. One lasts minutes, the other days
Vial strength is the same for both versions, so it cannot tell them apart
Both published human studies used the drug-affinity-complex version. The shorter-acting modified GRF 1-29 is sold under the same name. It has no human dosing study behind it
Every published quantity is per kilogram of body weight. No vial arithmetic follows from it without a weight
Early human work showed a growth-hormone rise over days, but it measured hormone levels only. No trial has reported a body-composition, strength or clinical outcome
A steady rise in growth hormone is a different state. The body normally makes pulses instead
The World Anti-Doping Agency bans growth-hormone releasing factors at all times. That covers in and out of competition
Questions about CJC-1295
Is CJC-1295 FDA-approved?
No. There is no prescribing label for it, so no approved dose exists — the regulatory status section above has the detail.
How is CJC-1295 taken?
By injection under the skin, per kilogram of body weight. The dosing page has every step, with the source on each row.
How does CJC-1295 differ from the other compounds in this class?
CJC-1295 has been studied in people, but it works through a different system from GLP-1 and amylin drugs. Its doses and results are not directly comparable with theirs.
What is not known about CJC-1295?
It does not prove that the same dose is appropriate in the United States or that uncommon and long-term risks are known.
Is there a CJC-1295 dosing schedule on this site?
Not a schedule — there is no approved schedule to publish here. What you get instead is the trial dosing program: the doses each arm received and how the protocol worked up to them. The studied range was 30–60 mcg per kilogram of body weight — the two of four rising single-dose levels the authors singled out as safe and relatively easy for healthy adults aged 21 to 61 to handle, using the version carrying the drug-affinity complex; a single injection raised growth hormone 2- to 10-fold for six days or more and IGF-I 1.5- to 3-fold for nine to eleven days. See what the trials tested.
Questions readers ask
What exactly does CJC-1295 do?
In the two published human studies it raised growth hormone and IGF-I, and held them up for days. A single injection lifted growth hormone two- to tenfold for six days or more. IGF-I stayed one-and-a-half to threefold above baseline for nine to eleven days.
What that achieves went untested. Both studies sampled blood and stopped there. No trial has reported a change in body shape, strength, or anything a person would notice.
Does CJC-1295 suppress testosterone?
Nobody has measured testosterone on it. The two human trials tracked growth hormone and IGF-I, and no sex hormone appeared on the list. So there is no evidence either way.
Both trials were short as well — one ran twenty-eight days, the other forty-nine, in healthy adults. Nothing has looked at what repeated use does to other hormones.
What are the downsides of CJC-1295?
The first is that you may not know which molecule you are holding. Two different substances are sold under this one name, and the vial strength is identical for both. The version studied in people carries a chemical arm that keeps it in the blood for days; the other clears in minutes.
The second is that no controlled trial of what it achieves was ever finished, and the company that made the long-acting form dropped it. Anti-doping rules ban growth-hormone releasing factors at all times, in and out of competition.
How many times a week should I take CJC-1295?
No published trial set a weekly pattern. Both human studies gave one injection and then watched what followed. Both quantities were set per kilogram of body weight, which is not a figure that converts without a weight.
What circulates is one to two milligrams a week, split across one or two injections of the long-acting version. A 2026 review prints that as a self-reported practice and says in the same table that such values are not clinically validated. Nothing has tested it.
4primary sources, each with the day we read it — open the documents used on this page
